This is an external link. Click “OK” to continue.
President, CEO and Chairman Kintara Therapeutics, USA
Prior to taking on his executive role at Kintara (Nasdaq), Robert was CFO of San Diego-based Heron Pharmaceuticals, a Nasdaq-listed commercial stage drug developer with a pipeline of acute pain therapeutics. During his tenure at Heron, the company raised more than $650 million and launched its second commercial drug product.
His career in the biotechnology sector began in 1997 at Arena Pharmaceuticals, where he rose to become CFO. While at Arena, he was involved with its IPO and financings raising more than $1.5 billion. For 10 years until 2020, Robert was a member of the Small Business Advisory Committee of the Financial Accounting Standards Board (FASB).
Robert is a member of the boards of ASLAN Pharmaceuticals (Nasdaq) and privately held FibroBiologics.
BBA St. Bonaventure University, USA
Robert is a founding board member of Day for Change, which has funded charities serving underprivileged and abused children in the San Diego area for 20 years.
“It’s a great time to work with Antibe’s impressive team to capture the full potential of a uniquely promising drug pipeline and platform.”
Emeritus Professor, Pharmacology William Harvey Research Institute, Queen Mary University, UK
Rod has spent much of his career researching inflammation and anti-inflammatory drugs. He was a member of the original group that demonstrated the mechanism of action of NSAIDs. He has also made significant advances in understanding how the glucocorticoids and cromone drugs produce their anti-inflammatory and anti-allergic actions.
He is the former President of the British Pharmacological Society. Rod has published more than 400 papers and is a co-author of a best-selling pharmacology textbook.
PhD Pharmacology University of London, UK
Rod is a recipient of several awards, including the William Withering Prize of the Royal College of Physicians, the Wellcome Gold Medal of the British Pharmacological Society, and the Lifetime Achievement Award of the International Association of Inflammation Societies.
“I believe that Antibe has made a landmark advance towards a safer treatment for inflammation.”
Chief Business Officer Knight Therapeutics, Canada
Amal is a senior pharmaceutical business development and licensing executive. She is Chief Business Officer for Knight Therapeutics, a company focused on in-licensing innovative, late-stage products for Canada and select international markets.
At Novartis Pharma AG, she held roles of Head of Partnering for General Medicines and Mature Products, Business Expansion Molecular Diagnostics, and Search and Evaluation IHC/Ophtha Franchises.
MBA University of Ottawa, Canada
Amal has led due diligence, deal structuring and negotiations for more than 20 transactions, with a combined deal value of $500M.
“The treatment of pain continues to pose a great challenge as there is a high unmet need for safe and effective pain therapies.”
Trained as a corporate lawyer and air force rescue pilot, Dan has since
JD Queen’s University, Canada
Dan’s leadership experience began with eight years as a military pilot.
“We think we’ve solved one of the significant, long-standing medical problems of our time.”
Vice Chairman (retired) Mastercard Incorporated, USA
Until 2020, he was Vice Chairman of MasterCard Incorporated, where he was involved in various public-private partnership initiatives. He previously served as President of International Markets, overseeing MasterCard’s business in 210 countries.
MBA Schulich School of Business, York University, Canada
Walt is the founder of Mastercard’s Center for Inclusive Growth, and has chaired the Centre for Social Impact at Queen’s University, and Convergence Finance. He has been a board member of Save the Children Canada, Big Brothers Big Sisters of Canada, the Royal Conservatory of Music, and the Sunnybrook Hospital Foundation.
“Better medicines for pain promise a better world for billions of people.”
Chief Financial Officer Abdera Therapeutics, Canada
Jennifer is a senior financial executive with a considerable breadth of experience in the biotechnology sector, as an analyst, portfolio manager, information provider and expert in corporate communications and investor relations. She is former Chief Financial Officer of Codex DNA, Inc.
Beginning her career as a healthcare equity analyst, Jennifer transitioned to managing biopharmaceutical-focused investment funds. She subsequently founded Laurient LLC, an independent equity research and competitive intelligence platform analyzing publicly traded biopharmaceutical companies.
Master of Health Administration (MHA) Cornell University, USA
Jennifer managed biopharmaceutical-focused investment funds for Morgan Stanley Dean Witter Advisors, Amerindo Investment Advisors and latterly at Franklin Templeton, where she co-managed the Franklin Biotechnology Discovery Fund.
“The severe shortcomings of today’s pain medications constitute one of the world’s most pressing medical needs. Patients deserve better. Antibe’s novel drug platform is a promising way forward – I am delighted to be a part of it.”
Former CEO MaRS Discovery District, Canada
Entrepreneurial Masters Program Massachusetts Institute of Technology, USA
Yung was recognized as one of Canada’s “Top 40 under 40” leaders earlier in his career and as chief executive of one of Canada’s “50 Best Managed Private Companies”.
“Antibe ranks amongst the most promising biotech companies that I’ve worked with.”
1. Audit Committee
2. Governance and Nomination Committee
3. HR and Compensation Committee